Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

The Effects of Escitalopram on Cytokines

Not Applicable

Conditions: Depression

Interventions: Drug: Escitalopram

First Posted Date: 2012-04-30

Last Posted Date: 2012-05-15

Lead Sponsor: Beitou Armed Forces Hospital, Taipei, Taiwan

Target Recruit Count: 25

Registration Number: NCT01587326

Locations: 🇨🇳
Beitou Armed Forces Hospital, Taipei, Taiwan

Escitalopram Treatment In Acute Stroke

Phase 4

Withdrawn

Conditions: Stroke

Interventions: Drug: Escitalopram
Drug: Placebo

First Posted Date: 2012-03-22

Last Posted Date: 2012-06-19

Lead Sponsor: University of Aarhus

Registration Number: NCT01561092

Locations: 🇩🇰
Neurology Department, University Hospital of Aarhus, Aarhus, Denmark
🇩🇰
Neurology Department, Glostrup Hospital, Glostrup, Denmark
🇩🇰
Neurology Department, Aalborg Hospital, Aalborg, Denmark

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Phase 4

Completed

Conditions: Irritable Bowel Syndrome
Panic Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2012-03-12

Last Posted Date: 2017-01-12

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 32

Registration Number: NCT01551225

Locations: 🇳🇱
Maastricht University Medical Center, Maastricht, Netherlands

Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Bupropion, Escitalopram
Drug: Escitalopram

First Posted Date: 2012-03-01

Last Posted Date: 2014-04-10

Lead Sponsor: Ewha Womans University

Target Recruit Count: 60

Registration Number: NCT01541475

Locations: 🇰🇷
Seoul National University Hospital, Biomedical Research Institute, Seoul, Korea, Republic of

Escitalopram in the Treatment of Postpartum Depression

Not Applicable

Completed

Conditions: Postpartum Depression

First Posted Date: 2012-02-07

Last Posted Date: 2012-02-10

Lead Sponsor: BC Women's Hospital & Health Centre

Target Recruit Count: 20

Registration Number: NCT01527474

Locations: 🇨🇦
Reproductive Mental Health Program, BC Women's Hospital, Vancouver, British Columbia, Canada

Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Phase 3

Withdrawn

Conditions: COPD
Anxiety

Interventions: Drug: escitalopram

First Posted Date: 2012-01-31

Last Posted Date: 2017-03-29

Lead Sponsor: Hull University Teaching Hospitals NHS Trust

Registration Number: NCT01522092

Locations: 🇬🇧
Respiratory Medicine, Clinical trials Unit, Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

Phase 4

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Agomelatine
Drug: Escitalopram

First Posted Date: 2011-12-01

Last Posted Date: 2013-12-18

Lead Sponsor: Baker Heart and Diabetes Institute

Target Recruit Count: 40

Registration Number: NCT01483053

Locations: 🇦🇺
Monash Medical Centre - Monash Health, Clayton, Victoria, Australia
🇦🇺
Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺
Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Phase 4

Completed

Conditions: Bipolar Depression

Interventions: Drug: Escitalopram
Drug: Celecoxib
Drug: Placebo

First Posted Date: 2011-11-24

Last Posted Date: 2024-04-29

Lead Sponsor: Loyola University

Target Recruit Count: 100

Registration Number: NCT01479829

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders

Phase 4

Completed

Conditions: Anxiety Disorder
Major Depressive Disorder (MDD)

Interventions: Drug: Escitalopram

First Posted Date: 2011-11-22

Last Posted Date: 2016-09-14

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 289

Registration Number: NCT01477203

Locations: 🇦🇹
Medical University of Vienna, Department for Psychiatrie and Psychotherapie, Vienna, Austria

Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)

Phase 4

Completed

Conditions: Postoperative Pain

Interventions: Drug: Escitalopram
Drug: Placebo

First Posted Date: 2011-09-08

Last Posted Date: 2013-06-05

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 120

Registration Number: NCT01430520

Locations: 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇰
Gentofte Hospital, Gentofte, Hellerup, Denmark
🇩🇰
Regionshospitalet Holstebro, Holstebro, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy